familyfeudtelevisionshow| CICC Lingnan received an overweight rating from Guosen Securities, and rising metal prices will increase profits in the mining sector.

Date: 4个月前 (05-12)View: 71Comments: 0

Transferred from: financial sector

This article is derived fromFamilyfeudtelevisionshowFinancial sector

May 12thFamilyfeudtelevisionshowIn 1998, CICC Lingnan was rated by Guoxin Securities, and Jinlingnan received three research reports in the past month.

familyfeudtelevisionshow| CICC Lingnan received an overweight rating from Guosen Securities, and rising metal prices will increase profits in the mining sector.

The company is expected to achieve revenue of 65.6 billion yuan (+ 18.5%), net profit of 690 million yuan (- 43.3%), net profit of 643 million yuan (- 45%) and operating net cash flow of 1.57 billion yuan (+ 45.3%) in 2023. According to the research report, mainly due to the decline in lead and zinc prices and the decline in lead and zinc concentrate production, the average annual price of domestic zinc in 2023 was 21635 yuan / ton, a year-on-year decrease of 14.2%. In 2023, the company's lead and zinc concentrate output was 170400 tons, down 6.2% from the same period last year. Foreign copper mining projects will become an important profit growth point. Looking forward to 2024, low processing fees for copper concentrate and zinc concentrate, which are rare for many years, will put some pressure on the smelting business, but the profit of the company's concentrate products will increase due to the rising prices of copper, zinc and lead. In the longer term, Maimeng Mine will produce 30,000 tons of copper and 30,000 tons of zinc annually, which will become an important profit growth point of the company.

Risk hint: copper, zinc prices or copper concentrate processing fees fall risk, mine production schedule is not as expected risk.

Tags:

Prev: davincidiamondsfreeslots| Yuyuan Shares (600655.SH): Terminate the issuance of A shares to specific targets in 2023 and withdraw the application documents
Next: livebaccaratonline| Microcore Biotech (688321.SH): Application for the III clinical trial of cidabenide in the treatment of colorectal cancer accepted

Related articlesNo more
︿